We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Ablation Therapy Could Treat Stomach Disorders by Correcting Abnormal Electrical Activation

By HospiMedica International staff writers
Posted on 04 May 2022

When dysrhythmic activity occurs in the heart, it results in irregular heartbeat, and a condition called atrial fibrillation. More...

This is often treated with ablation therapy, the precise ‘burning’ of tissue to control the naturally occurring electricity in the heart. Now, researchers have demonstrated that the technique could also be applied to control the underlying bioelectrical “slow wave” activity in the stomach for the potential treatment of disorders of gastric function.

Last year, a team of researchers from the Auckland Bioengineering Institute (Auckland, New Zealand) had published the initial results of their research performing ablation in the stomach, demonstrating that it was possible to use ablation to block the electrical activation of the stomach in localized regions. In normal circumstances the stomach is coordinated by underlying bioelectrical “slow wave” activity, which coordinates the contraction of the muscles that mix and move contents into and through the gastrointestinal (GI) tract. When these electrical slow waves don’t work as they normally should, described as ‘stomach dysrhythmias’, it can lead to severe GI disorders and symptoms of nausea, vomiting, pain and bloating.

“The more recent paper builds on that foundational work, where we have targeted ablation to inhibit specific sites of electrical activation in the stomach,” said Dr. Tim Angeli-Gordon who supervised the research. “This is an important advance because we have now shown that we can eliminate abnormal electrical activation with ablation, and also that the normal electrical activation of the stomach can be restored after ablation. Although these studies were done in our pre-clinical lab, they demonstrate the powerful potential of ablation in the stomach which may now be able to be translated as a therapy for patients suffering from gastrointestinal disorders.”

Related Links:
Auckland Bioengineering Institute 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Pedicle Screw Platform
CREO DLX Stabilization System
New
Anesthesia Cart
UTGSU-333369-DKB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: the deep tissue in vivo sound printing (DISP) platform, which combines ultrasound with low-temperature–sensitive liposomes loaded with crosslinking agents (Photo courtesy of Elham Davoodi and Wei Gao/Caltech)

New Ultrasound-Guided 3D Printing Technique to Help Fabricate Medical Implants

3D bioprinting technologies hold considerable promise for advancing modern medicine by enabling the production of customized implants, intricate medical devices, and engineered tissues designed to meet... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.